Cytokinetics launched EARTH-HCM, an online tool analyzing real-world data to improve awareness and access to HCM care.
Quiver AI Summary
Cytokinetics has launched EARTH-HCM, an interactive online tool aimed at improving awareness and understanding of hypertrophic cardiomyopathy (HCM) in the U.S. Developed with input from prominent academic institutions, the tool utilizes real-world claims data to analyze patient demographics, treatment options, outcomes, healthcare utilization, and costs. EARTH-HCM is intended for a diverse audience, including patients, healthcare providers, and policymakers, and aims to highlight disparities in care and promote equitable access to treatment. By offering insights into the geographical distribution of HCM and enhancing education surrounding the disease, the tool aspires to improve patient outcomes and encourage better treatment strategies. The platform will be regularly updated and is accessible at www.earth-hcm.com.
Potential Positives
- Launch of EARTH-HCM, an innovative online public health education tool, enhances Cytokinetics' position as a leader in advancing awareness and education about hypertrophic cardiomyopathy (HCM).
- Collaborative development with esteemed academic institutions strengthens the credibility and reach of the tool, appealing to a wide array of stakeholders including patients, healthcare providers, and researchers.
- Regular updates and expansion to include global data signify Cytokinetics' commitment to continuous improvement and relevance in the healthcare landscape.
Potential Negatives
- The press release relies heavily on forward-looking statements regarding the potential benefits and regulatory approval of aficamten, which may create uncertainty if these expectations are not met.
- The mention of significant geographical disparities in care for HCM could imply that the company's current interventions may not be adequately addressing patient needs effectively, which could reflect poorly on its reputation.
- Despite the emphasis on innovative tools, there is no clear indication of how the company plans to implement or fund the ongoing updates and expansions of the EARTH-HCM tool, potentially raising concerns about sustainability.
FAQ
What is EARTH-HCM?
EARTH-HCM is an interactive online tool that visualizes and analyzes the burden of disease in hypertrophic cardiomyopathy (HCM) using real-world data.
Who developed the EARTH-HCM tool?
Cytokinetics developed EARTH-HCM in collaboration with leading academic institutions and experts in hypertrophic cardiomyopathy.
How does EARTH-HCM benefit patients?
EARTH-HCM enhances awareness, education, and equitable access to care for patients with hypertrophic cardiomyopathy.
What kind of data does EARTH-HCM use?
It utilizes de-identified claims data from Symphony Health’s Integrated Dataverse, representing a wide range of healthcare facilities across the U.S.
Where can I access the EARTH-HCM tool?
EARTH-HCM can be accessed online at www.earth-hcm.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CYTK Insider Trading Activity
$CYTK insiders have traded $CYTK stock on the open market 42 times in the past 6 months. Of those trades, 0 have been purchases and 42 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- ROBERT I BLUM (President & CEO) has made 0 purchases and 10 sales selling 113,361 shares for an estimated $5,173,844.
- FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 21 sales selling 69,908 shares for an estimated $3,468,023.
- ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 6 sales selling 55,001 shares for an estimated $2,431,164.
- WENDALL WIERENGA has made 0 purchases and 3 sales selling 5,936 shares for an estimated $305,785.
- JOHN T HENDERSON sold 1,780 shares for an estimated $89,747
- ROBERT ARTHUR HARRINGTON sold 900 shares for an estimated $38,250
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CYTK Hedge Fund Activity
We have seen 149 institutional investors add shares of $CYTK stock to their portfolio, and 215 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ removed 4,610,302 shares (-95.5%) from their portfolio in Q4 2024, for an estimated $216,868,606
- DARWIN GLOBAL MANAGEMENT, LTD. removed 4,575,558 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $241,589,462
- DEEP TRACK CAPITAL, LP added 1,870,094 shares (+296.9%) to their portfolio in Q4 2024, for an estimated $87,969,221
- PFM HEALTH SCIENCES, LP removed 1,757,192 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $82,658,311
- FMR LLC removed 1,299,568 shares (-10.7%) from their portfolio in Q4 2024, for an estimated $61,131,678
- CAPITAL INTERNATIONAL INVESTORS added 1,096,164 shares (+inf%) to their portfolio in Q4 2024, for an estimated $51,563,554
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,062,136 shares (+11.0%) to their portfolio in Q4 2024, for an estimated $49,962,877
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CYTK Analyst Ratings
Wall Street analysts have issued reports on $CYTK in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/18/2024
- H.C. Wainwright issued a "Buy" rating on 11/18/2024
To track analyst ratings and price targets for $CYTK, check out Quiver Quantitative's $CYTK forecast page.
$CYTK Price Targets
Multiple analysts have issued price targets for $CYTK recently. We have seen 2 analysts offer price targets for $CYTK in the last 6 months, with a median target of $93.5.
Here are some recent targets:
- An analyst from Morgan Stanley set a target price of $67.0 on 03/07/2025
- Joseph Pantginis from H.C. Wainwright set a target price of $120.0 on 10/17/2024
Full Release
Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care
SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (
E
pidemiology,
A
wareness,
R
eal-world
T
reatment and
H
ealth Outcomes in
HCM
), an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic institutions, that leverages real-world, de-identified claims data to visualize and analyze population differences in patient characteristics, treatments, clinical outcomes, healthcare resource utilization and costs in hypertrophic cardiomyopathy (HCM) in the U.S.
EARTH-HCM is an innovative, user-friendly, interactive tool designed to bridge the gap in awareness and education about HCM by providing insights into the treatment landscape and disparities in care. The tool was engineered to serve an array of stakeholders, including patients and caregivers, clinicians, pharmacists, researchers, policy decision-makers, payors and patient advocacy groups. EARTH-HCM was developed with experts in HCM including cardiologists, clinical pharmacy specialists and data scientists from leading academic institutions including Oregon Health & Science University; Perelman School of Medicine at the University of Pennsylvania; Yale School of Medicine; Massachusetts General Hospital, Harvard Medical School; and Georgia Institute of Technology.
“Until now, limited evidence has been available on the geographical distribution of HCM and its impact on patient outcomes. EARTH-HCM aims to advance research, uncover knowledge gaps, and investigate disparities in care, ultimately promoting more equitable access, not just for our company, but for the entire HCM community,” said Sanatan Shreay, Ph.D., Cytokinetics’ Executive Director, Head of Health Economics and Outcomes Research. “We are proud to have led the development of this innovative tool to further HCM education, raise awareness, enhance treatment strategies and empower patients to feel more connected to their local communities.”
EARTH-HCM uses data from Symphony Health’s Integrated Dataverse (IDV) prescription claims database including real-world, deidentified claims from over 65,000 pharmacies, 1,500 hospitals, 800 outpatient facilities and 80,000 physician practices across the U.S., currently representing a majority of patients with HCM diagnosed between 2016 and 2023. EARTH-HCM will be updated regularly with publicly available data and expanded to include data from global geographies.
“Alongside advancements in the treatment landscape for HCM, diagnosis rates around the U.S. are increasing. Currently, most patients with HCM receive treatment at centers of excellence, however, these institutions are not easily accessible to all patients,” said Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University and member of the EARTH-HCM Committee. “A tool like EARTH-HCM can help both patients and healthcare providers understand current geographical disparities in the treatment of HCM as can hopefully lead to improved recognition, care and outcomes.”
“EARTH-HCM is a first-of-its-kind tool in HCM offering a comprehensive view of HCM patients everywhere in the U.S.,” said Ralph Riello, PharmD, Yale School of Medicine, Clinical Pharmacy Specialist and member of the EARTH-HCM Committee. “With this unprecedented level of insight, we can identify where eligible patients are, engage providers and payors to address the burden of disease in HCM and ultimately work to improve patient outcomes and healthcare costs.”
EARTH-HCM can be accessed online at
www.earth-hcm.com
.
About Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller and stiffer, and thus the ventricle becomes less able to relax and fill with blood. This ultimately limits the heart’s pumping function, resulting in reduced exercise capacity and symptoms including chest pain, dizziness, shortness of breath, or fainting during physical activity. HCM is the most common monogenic inherited cardiovascular disorder, with approximately 280,000 patients diagnosed, however, there are an estimated 400,000-800,000 additional patients who remain undiagnosed in the U.S.
1
,
2
,
3
Two-thirds of patients with HCM have obstructive HCM (oHCM), where the thickening of the cardiac muscle leads to left ventricular outflow tract (LVOT) obstruction, while one-third have non-obstructive HCM (nHCM), where blood flow isn’t impacted, but the heart muscle is still thickened. People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.
4
People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.
5
A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.
About Cytokinetics
Cytokinetics is a leading muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a pioneer in muscle and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of
aficamten,
a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM).
Aficamten
is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing
omecamtiv mecarbil
, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from
aficamten,
for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit
www.cytokinetics.com
and follow us on
X
,
LinkedIn
,
Facebook
and
YouTube
.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied relating to the properties or potential benefits of
aficamten
or any of our other drug candidates, our ability to obtain regulatory approval for
aficamten
for the treatment of obstructive hypertrophic cardiomyopathy or any other indication from FDA or any other regulatory body in the United States or abroad, and the labeling or post-marketing conditions that FDA or another regulatory body may require in connection with the approval of
aficamten
. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
References:
CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575
Symphony Health 2016-2021 Patient Claims Data DoF;
Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.
Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.
Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
